linjc16/ctgov huggingface dataset:
Identifying Underserved Individuals inTexas With Hereditary Cancer Risk Using Mobile Mammography Units and Telegenetics.

Study Overview
=================
Brief Summary
-----------------
Identifying women at risk for hereditary cancer potentiates prevention, early detection or personalised treatment against cancer. We using mobile mammography units will provide genetic sceening and testing services to underserved women coming for thier mammograms to these units.

Detailed Description
-----------------
Objectives: To identify underserved women at risk for hereditary breast and colorectal cancers and would be eligible for standard of care genetic counseling and testing using national screening guidelines. To provide education to providers and patients regarding hereditary cancers using previously IRB approved educational material and short video.

Official Title
-----------------
Identifying Underserved Individuals inTexas With Hereditary Cancer Risk Using Mobile Mammography Units and Telegenetics.

Conditions
-----------------
Ovarian Cancer, Breast Cancer, Colorectal Cancer

Intervention / Treatment
-----------------
* Behavioral: Genetic Testing and Counseling
* Behavioral: Screening Form


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Any woman scheduled at Project VALET mammography screening mobile units will be eligible for this study. Exclusion Criteria:

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Screening
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: Genetic Testing and Counseling<br>Participants will be given a saliva collection kit to collect a saliva sample for hereditary cancer and genetic testing. The kit includes all standard paperwork and instructions for collecting the sample and shipping the kit back to the genetic testing company (Invitae). | Behavioral: Genetic Testing and Counseling<br>* Participants will be asked to collect a saliva sample for hereditary cancer and genetic testing<br>|
| Other: Screening Form<br>Participants will complete a screening form to assess your risk of hereditary breast and colorectal cancers. | Behavioral: Screening Form<br>* Participant will be answering demographic details<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To identify underserved women at risk for hereditary breast and colorectal cancers eligible for standard-of-care genetic counseling using national screening guidelines. |  | through study completion; an average of 1 year. |
The Association Between Autoimmune or Inflammation and Thyroid Disease

Study Overview
=================
Brief Summary
-----------------
This study aims to evaluate the effects of thyroid functions on energy homeostasis and inflammation.

Detailed Description
-----------------
The subjects were enrolled for evaluation of thyroid functions. The associations between thyroid function and energy homeostasis and inflammation will be assessed.

Official Title
-----------------
The Relationship of Vascular Cell Adhesion Molecule 1, C-reactive Protein, Brain-derived Neurotrophic Factor, Orexin and Depressive Symptoms in the Subjects With Thyroid Disease

Conditions
-----------------
THYROTOXICOSIS

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Subjects visits outpatient department due to a suspicion of thyroid disease Exclusion Criteria: Psychological disorders, severe inflammatory or infection diseases.

Ages Eligible for Study
-----------------
Minimum Age: 20 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| brain-derived neurotrophic factor | BDNF | 3 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| vascular cell adhesion molecule 1 (VCAM-1) | Inflammation | 3 months | 
| C-reactive protein (CRP) | Inflammation | 3 months | 
| Orexin | Psychological assessment | 3 month | 
| Zung Self-Rating Depression Scale (Zung SDS) | Depressive symptom | 3 month | 
| Body composition | fat component | 3 month | 
| ankle brachial index (ABI) | Arterial stiffness | 3 months | 
| pulse wave velocity (PWV) | Arterial stiffness | 3 months | 
| mean arterial pressure (MAP) | Arterial stiffness | 3 months |
Accuracy of Non-invasive Continuous CO2-Monitoring

Study Overview
=================
Brief Summary
-----------------
Arterial carbon dioxide partial pressure (PaCO2) is an essential indicator of ventilation and respiratory function. It is routinely tested invasively by arterial blood gas analysis (ABGA) but recently developed miniaturized carbon dioxide tension sensors promise non-invasive and continuous transcutaneous PCO2 (PtcCO2) monitoring. We, the researchers at University Hospital, Basel, Switzerland, determined the accuracy of two PtcCO2 monitors (TOSCA 500 with Sensor 92, Linde Medical Sensors AG, Basel; and Sentec Digital Monitor with V-Sign Sensor, Sentec AG, Therwil) for measurement of single values and trends in PaCO2 in critically ill patients, using ABGA as a reference.

Detailed Description
-----------------
Measurement of SO2 is used in nearly every patient receiving anesthesia or sedation, whereas monitoring of pCO2 is important in patients during and shortly after major surgery and in critically ill patients. But measurement of pCO2 requires arterial blood sampling and laboratory testing. Non-invasive monitors for continuous assessment of arterial pCO2 have been developed but their accuracy and feasibility were insufficient to make them useful in the clinical setting. Recently, a new digital system for continuous and non-invasive monitoring of arterial pCO2 and SO2 has been introduced (SenTec Digital Monitor System, SenTec AG, Therwil, Switzerland). This present study has been designed to evaluate the accuracy of the SenTec V-SignTM monitoring system for measuring pCO2 in comparison with repeated arterial blood gas testing in the operation room and in the intensive care unit.

Official Title
-----------------
The Accuracy of Non-invasive Continuous Carbon Dioxide Monitoring by the Sentec V-Sign Digital Monitor System

Conditions
-----------------
Blood Gas Monitoring, Transcutaneous

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients older than 18 years with clinical indication of repeated arterial blood gas analyses Exclusion Criteria: No informed consent

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
carbon dioxide, monitoring, major surgery, repeated blood gas testing, carbon dioxide monitoring
Phase I Trial of Periocular Topotecan in Retinoblastoma

Study Overview
=================
Brief Summary
-----------------
This is a dose-escalation study aimed to assess the toxicity (and marginally the activity) of periocular topotecan in patients with relapsed-resistant retinoblastoma.

Detailed Description
-----------------
Patients with bilateral retinoblastoma who have relapsed after attempts of conservative therapy with standard regimens such as carboplatin, etoposide, vincristine and external beam radiotherapy who face immediate enucleation of their single remaining eye are eligible for this protocol. Starting dose of topotecan will be 0.5 mg and dose escalation will be done by the accelerated titration method. Any Grade 3 ocular toxicity or grade 4 non ocular toxicity will be designed as the dose limiting toxicity. Grade 2 scleral toxicity will be considered for DLT. In case of grade 2 ocular toxicity or grade 3 systemic toxicity, the escalation dose will be 0.25 mg. Maximal dose will be 2 mg.

Official Title
-----------------
Toxicity and Activity of Periocular Topotecan in Children With Retinoblastoma

Conditions
-----------------
Retinoblastoma

Intervention / Treatment
-----------------
* Drug: Topotecan


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Group Vb (Reese Ellsworth) Relapsed or progressed after carboplatin-based regimens and external beam radiotherapy Enucleation of the contralateral eye Normal renal and liver function Exclusion Criteria: Presence of glaucoma, rubeosis iridis, anterior chamber extension Extraocular disease Adequate follow up impossible for social reasons

Ages Eligible for Study
-----------------
Maximum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Topotecan|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Dose limiting toxicity |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Response rate, description of toxicity, pharmacokinetic profile |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
topotecan, periocular, chemotherapy
NI-0801 in Allergic Contact Dermatitis

Study Overview
=================
Brief Summary
-----------------
The purpose of the study is to assess the effect of a single dose of NI-0801 on the severity of nickel-induced allergic contact dermatitis.

Official Title
-----------------
A Proof-of-Principle Study Investigating the Effect of Single Doses of NI-0801 on Nickel Induced Contact Dermatitis

Conditions
-----------------
Allergic Contact Dermatitis

Intervention / Treatment
-----------------
* Drug: Placebo
* Drug: NI-0801


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Aged ≥ 18 and ≤ 70 years Either male or a female lacking childbearing potential Previously documented nickel allergy Exclusion Criteria: Any medical condition that, in the opinion of the investigator, would interfere with safe completion of the trial or that would prevent subjects from providing informed consent. Known or previous diagnosis of malignancy Known current active tuberculosis or a history of active TB within 12 months of screening Known infection with HIV, Hepatitis B or C

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Allocation: Randomized


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Placebo Comparator: Placebo<br> | Drug: Placebo<br>* single i.v. administration<br>|
| Experimental: NI-0801<br> | Drug: NI-0801<br>* single i.v. administration<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Effect of NI-0801 administration on the severity of the cutaneous response to Nickel challenge as measured using the score system of the DKG (Deutsche Kontakt-Allergie Gruppe). |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Safety and tolerability of NI-0801 as measured by the incidence and severity of treatment emergent adverse events. |  |  |
Impaired Insulin-like Growth Factor-1 (IGF-1) Generation Causes Protein Catabolism and Poor Growth in Children With Crohn Disease

Study Overview
=================
Brief Summary
-----------------
The investigators will prospectively recruit 26 children with moderate - severe active Crohn disease (PCDAI >30). Results will be compared to 26 patients in sustained remission (PCDAI <10 and physician global assessment of remission over the previous 6 months) who are matched for age and gender. Subjects will be studied at baseline and six months. The primary study end-points will be leucine rate of appearance (a measure of protein breakdown) and IGF-1 levels. This study will test the hypothesis that children with greater disease severity will have worse longitudinal growth and protein catabolism. The investigators will also explore the secondary hypothesis that children with Crohn disease have abnormal IGF-1 generation which is linked to underlying inflammation and disease severity.

Official Title
-----------------
Impaired IGF-1 Generation Causes Protein Catabolism and Poor Growth in Children With Crohn Disease

Conditions
-----------------
Crohns Disease

Intervention / Treatment
-----------------
* Other: Examinations


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diagnosed with Crohn disease by endoscopy and histologic samples Chronological and/or bone age 6-15 years old Tanner 1 - 2 Willing to participate in our longitudinal evaluation Exclusion Criteria: Concomitant persistent chronic infectious disease Inflammatory bowel disease not diagnosed as Crohn disease Immunological disorder (excluding Crohn disease) Associated severe concomitant chronic illnesses (CF, liver failure) Pregnancy

Ages Eligible for Study
-----------------
Minimum Age: 5 Years
Maximum Age: 15 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Diagnostic<br> | Other: Examinations<br>* Growth hormone stimulation testing, Protein turnover, Dexa scan, Bone age x-ray<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Height velocity |  | 6 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Protein catabolism |  | 6 months |
The Characteristics and Role of Mucosal Microbiome After Treatment of Clostridioides Difficile Infection

Study Overview
=================
Brief Summary
-----------------
This research is being done to study the ability of C. difficile to colonize the colonic mucosa of individuals with no prior history of C. difficile infection.

Detailed Description
-----------------
The ability of C. difficile to colonize the mucosa of the colon will be studied in healthy individuals with no history of C. difficile infection who are undergoing colonoscopy for colon cancer/polyp screening purposes.

Official Title
-----------------
The Characteristics and Role of Mucosal Microbiome After Treatment of Clostridioides Difficile Infection

Conditions
-----------------
Clostridioides Difficile Infection

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adults aged 18 and over No history of C. difficile infection Undergoing clinically indicated colonoscopy for colon cancer screening or colon polyp surveillance purposes in the absence of active GI symptoms. Exclusion Criteria: Known active pregnancy Other known active gastrointestinal infectious process Inflammatory gastrointestinal conditions (microscopic colitis, inflammatory bowel disease, Celiac disease) Vulnerable adults Any other disease(s), condition(s) or habit(s) that would interfere with completion of study, or in the judgment of the investigator would potentially interfere with compliance to this study or would adversely affect study outcomes

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Presence of C. difficile within the sigmoid colonic mucosal tissue | C. difficile identified on fluorescence microscopy via FISH staining | 1 day (At time of biopsy) |
microRNA Expression in Renal Cell Carcinoma

Study Overview
=================
Brief Summary
-----------------
In this study, renal cell carcinoma (RCC) related miRNA and the target genes of related miRNA will be examined in order to investigate the role of miRNA in the formation of RCC and look for the biomarker of RCC.

Detailed Description
-----------------
Due to the lack of specific indicators for the early diagnosis of RCC, the RCC patients often have distant metastasis when diagnosed and their five-year survival rate is much low. Therefore, the biological markers of RCC are needed for early detection, early treatment and improvement of the survival rate of RCC patients. MiRNA and tumor are closely related. MiRNA can control the important cancer-related genes and participate in the tumor cell proliferation, apoptosis, invasion and angiogenesis. In this study, RCC related miRNA and the target genes of related miRNA will be examined,and the relationship between RCC related miRNA and the RCC pathological types, TNM (tumor-nodes-metastasis) stages and prognosis will be analyzed. The purpose of this study is to investigate the role of miRNA in the formation of RCC and look for the biomarker of RCC.

Official Title
-----------------
microRNA Expression in Renal Cell Carcinoma

Conditions
-----------------
Carcinoma, Renal Cell

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with primary renal cell carcinoma. Subjects who agree to participate in the study and sign the informed consent. Exclusion Criteria: Patients with secondary renal cell carcinoma. Subjects who refuse to participate in the study and sign the informed consent.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Carcinoma, Renal Cell, MicroRNAs
Renal Replacement Therapy Plus Extracorporeal Carbon Dioxide Removal

Study Overview
=================
Brief Summary
-----------------
This study aims to assess whether in patients with acute kidney injury (AKI) requiring mechanical ventilation, a strategy that combines renal replacement therapy (RRT) and extracorporeal carbon dioxide removal (ECCO2R) allows reduction of tidal volume and plateau pressure. Systemic Inflammatory Response and Safety Variables will also be analysed.

Official Title
-----------------
Combined Strategy of Renal Replacement Therapy Plus Extracorporeal Carbon Dioxide Removal in Patients With Acute Kidney Injury

Conditions
-----------------
Acute Kidney Injury

Intervention / Treatment
-----------------
* Device: RRT plus ECCO2R


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with acute kidney injury (AKI) requiring renal-replacement therapy and mechanical ventilation of duration ≥ 48 hours Exclusion Criteria: little chance of survival at 24 h (according to clinical judgment), pregnancy, mechanical ventilation with expected duration lower than 48h, age under 18 and over 90

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: RRT plus ECCO2R<br> | Device: RRT plus ECCO2R<br>* Patients with acute kidney injury will be treated with Renal replacement therapy associated to extracorporeal carbon dioxide removal in a single treatment<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Achievement of tidal volume reduction to 4 mL/kg while maintaining pH and PaCO2 to ± 20% of baseline values |  | 72 hours | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Evaluation of inflammatory mediators release in plasma samples of patients | Plasma Concentrations of interleukin 6, interleukin 8, interleukin 1 beta, tumor necrosis factor alpha | 72 hours | 
| Assessment of the changes in pH |  | 72 hours | 
| Assessment of the changes in PaCO2 |  | 72 hours | 
| Assessment of the changes in PaO2 |  | 72 hours | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
AKI, Extracorporeal Carbon Dioxide Removal, Renal Replacement Therapy, Mechanical Ventilation